The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma.
Dopamine agonist
Endoscopic transsphenoidal resection
Observational cohort
Pituitary tumour
Prolactinoma
Randomised clinical trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Sep 2021
25 Sep 2021
Historique:
received:
11
11
2020
accepted:
05
09
2021
entrez:
26
9
2021
pubmed:
27
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side effects negatively impact health-related quality of life (HRQoL). Endoscopic transsphenoidal resection is reserved for patients with severe side effects, or with DA-resistant prolactinoma. Surgery has a good safety profile and high probability of remission and may thus deserve a more prominent place in prolactinoma treatment. The hypothesis for this study is that early or upfront surgical resection is superior to DA treatment both in terms of HRQoL and remission rate in patients with a non-invasive prolactinoma of limited size. We present a combined randomised clinical trial and observational cohort study design, which comprises three unblinded randomised controlled trials (RCTs; PRolaCT-1, PRolaCT-2, PRolaCT-3), and an observational study arm (PRolaCT-O) that compare neurosurgical counselling, and potential subsequent endoscopic transsphenoidal adenoma resection, with current standard care. Patients with a non-invasive prolactinoma (< 25 mm) will be eligible for one of three RCTs based on the duration of pre-treatment with DAs: PRolaCT-1: newly diagnosed, treatment-naïve patients; PRolaCT-2: patients with limited duration of DA treatment (4-6 months); and PRolaCT-3: patients with persisting prolactinoma after DA treatment for > 2 years. PRolaCT-O will include patients who decline randomisation, due to e.g. a clear treatment preference. Primary outcomes are disease remission after 36 months and HRQoL after 12 months. Early or upfront surgical resection for patients with a limited-sized prolactinoma may be a reasonable alternative to the current standard practice of DA treatment, which we will investigate in three RCTs and an observational cohort study. Within the three RCTs, patients will be randomised between neurosurgical counselling and standard care. The observational study arm will recruit patients who refuse randomisation and have a pronounced treatment preference. PRolaCT will collect randomised and observational data, which may facilitate a more individually tailored practice of evidence-based medicine. US National Library of Medicine registry (ClinicalTrials.gov) NCT04107480 . Registered on 27 September 2019, registered retrospectively (by 2 months).
Sections du résumé
BACKGROUND
BACKGROUND
First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%. Therefore, many patients require prolonged DA treatment, while side effects negatively impact health-related quality of life (HRQoL). Endoscopic transsphenoidal resection is reserved for patients with severe side effects, or with DA-resistant prolactinoma. Surgery has a good safety profile and high probability of remission and may thus deserve a more prominent place in prolactinoma treatment. The hypothesis for this study is that early or upfront surgical resection is superior to DA treatment both in terms of HRQoL and remission rate in patients with a non-invasive prolactinoma of limited size.
METHODS
METHODS
We present a combined randomised clinical trial and observational cohort study design, which comprises three unblinded randomised controlled trials (RCTs; PRolaCT-1, PRolaCT-2, PRolaCT-3), and an observational study arm (PRolaCT-O) that compare neurosurgical counselling, and potential subsequent endoscopic transsphenoidal adenoma resection, with current standard care. Patients with a non-invasive prolactinoma (< 25 mm) will be eligible for one of three RCTs based on the duration of pre-treatment with DAs: PRolaCT-1: newly diagnosed, treatment-naïve patients; PRolaCT-2: patients with limited duration of DA treatment (4-6 months); and PRolaCT-3: patients with persisting prolactinoma after DA treatment for > 2 years. PRolaCT-O will include patients who decline randomisation, due to e.g. a clear treatment preference. Primary outcomes are disease remission after 36 months and HRQoL after 12 months.
DISCUSSION
CONCLUSIONS
Early or upfront surgical resection for patients with a limited-sized prolactinoma may be a reasonable alternative to the current standard practice of DA treatment, which we will investigate in three RCTs and an observational cohort study. Within the three RCTs, patients will be randomised between neurosurgical counselling and standard care. The observational study arm will recruit patients who refuse randomisation and have a pronounced treatment preference. PRolaCT will collect randomised and observational data, which may facilitate a more individually tailored practice of evidence-based medicine.
TRIAL REGISTRATION
BACKGROUND
US National Library of Medicine registry (ClinicalTrials.gov) NCT04107480 . Registered on 27 September 2019, registered retrospectively (by 2 months).
Identifiants
pubmed: 34563236
doi: 10.1186/s13063-021-05604-y
pii: 10.1186/s13063-021-05604-y
pmc: PMC8465768
doi:
Banques de données
ClinicalTrials.gov
['NCT04107480']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653Subventions
Organisme : ZonMw
ID : 843002806
Pays : Netherlands
Informations de copyright
© 2021. The Author(s).
Références
Pituitary. 2008;11(3):247-54
pubmed: 18270842
Pituitary. 2014 Apr;17(2):150-6
pubmed: 23504371
Surg Neurol. 2009 Oct;72(4):336-40
pubmed: 19604551
Endocrine. 2017 Feb;55(2):618-624
pubmed: 27601019
Cochrane Database Syst Rev. 2014 Apr 29;(4):MR000034
pubmed: 24782322
Med Care. 1993 Mar;31(3):247-63
pubmed: 8450681
Neurol Med Chir (Tokyo). 2009 Jan;49(1):1-7
pubmed: 19168995
Pituitary. 2015 Oct;18(5):752-76
pubmed: 25605584
Endocrinol Metab Clin North Am. 2015 Mar;44(1):105-15
pubmed: 25732647
Clin Endocrinol (Oxf). 1993 Sep;39(3):323-9
pubmed: 7900937
Eur J Endocrinol. 2012 Jul;167(1):17-25
pubmed: 22511808
Biomed Pharmacother. 1994;48(3-4):167-74
pubmed: 7993981
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Eur J Endocrinol. 2007 Aug;157(2):133-9
pubmed: 17656590
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
Neuroendocrinology. 2006;83(3-4):240-8
pubmed: 17047389
Neurosurgery. 2008 May;62(5):1006-15; discussion 1015-7
pubmed: 18580798
Pituitary. 2014 Aug;17(4):307-19
pubmed: 23907570
J Gen Intern Med. 2020 May;35(5):1396-1404
pubmed: 32193818
Croat Med J. 2012 Jun;53(3):224-33
pubmed: 22661135
Pituitary. 2015 Feb;18(1):86-100
pubmed: 24682940
Surg Endosc. 2015 Jun;29(6):1270-80
pubmed: 25270611
JAMA. 2017 Feb 7;317(5):516-524
pubmed: 28170483
Clin Endocrinol (Oxf). 2015 Mar;82(3):412-21
pubmed: 25039500
Neurol Med Chir (Tokyo). 2013;53(7):501-10
pubmed: 23883562
BMJ. 2016 Feb 08;352:i493
pubmed: 26858277
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
J Endocrinol Invest. 2016 Dec;39(12):1377-1382
pubmed: 27245604
Pituitary. 2013 Dec;16(4):545-53
pubmed: 23239049
World Neurosurg. 2016 Mar;87:65-76
pubmed: 26548828
Clin Endocrinol (Oxf). 2014 Jun;80(6):863-8
pubmed: 24274365
N Engl J Med. 1994 Oct 6;331(14):904-9
pubmed: 7915824
J Clin Endocrinol Metab. 2009 Aug;94(8):2729-34
pubmed: 19491225
Eur J Endocrinol. 2016 Sep;175(3):R89-96
pubmed: 27207245
J Clin Neurosci. 2015 Nov;22(11):1785-91
pubmed: 26277642
Pituitary. 2010;13(1):68-77
pubmed: 19697135
Acta Endocrinol (Copenh). 1992 Jun;126(6):489-94
pubmed: 1642081
J Clin Endocrinol Metab. 2011 Feb;96(2):273-88
pubmed: 21296991
Pituitary. 2017 Oct;20(5):489-498
pubmed: 28884415
Acta Neurochir (Wien). 2016 May;158(5):933-42
pubmed: 26970763
Pituitary. 2009;12(3):153-7
pubmed: 18594989
Neurosurg Focus. 2011 Apr;30(4):E10
pubmed: 21456921
Pituitary. 2003 Sep;6(2):81-7
pubmed: 14703017
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31665485
J Neurol Surg B Skull Base. 2017 Apr;78(2):125-131
pubmed: 28321375
Clin Neurol Neurosurg. 2009 Feb;111(2):119-22
pubmed: 18986756
JAMA Intern Med. 2014 Dec;174(12):1930-3
pubmed: 25329919
PLoS One. 2017 Nov 9;12(11):e0187477
pubmed: 29121647